CurrentEndo — Type 2 & other diabetes

Diabetes mellitus and 10-year clinical outcomes after percutaneous coronary intervention with drug-eluting stents: insights from the DECADE cooperation

2026-11-14T10:46:26.825Z

Meta-analysis · Cardiovasc Diabetol, 2026.

Long-term cumulative exposure and longitudinal profiles of the cholesterol, high density lipoprotein, and glucose (CHG) index, versus the metabolic score for insulin resistance (METS-IR) for incident heart failure risk: A prospective cohort study

2026-11-14T06:45:51.583Z

Cohort study · Diabetes Res Clin Pract, 2026.

Global Trends and Exposure Profiling of Early‐Onset Type 2 Diabetes: An Ecological Analysis Using Machine Learning

2026-11-13T19:45:41.967Z

Diagnostic or prognostic study · Diabetes Obes Metab, 2026.

Serum 25(OH)D and diabetes risk in adults with prediabetes: evidence, potential mechanisms, and implications

2026-11-13T19:45:41.967Z

Research article · J Clin Endocrinol Metab, 2026.

Sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in type 2 diabetes and chronic kidney disease: Nationwide target trial emulation

2026-11-13T19:45:41.967Z

Research article · Diabetes Res Clin Pract, 2026.

Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform

2026-11-13T18:46:09.627Z

Cohort study · Diabetes Obes Metab, 2026.

Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial

2026-11-13T18:46:09.627Z

Randomized controlled trial · BMJ, 2026.

Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis

2026-11-13T18:46:09.627Z

Meta-analysis · Diabetes Obes Metab, 2026.

Ethnic differences in the prevalence and factors associated with prediabetes and diabetes among tested adults in Australian primary care (2014–2024)

2026-11-13T18:46:09.627Z

Cross-sectional study · BMJ Open Diabetes Res Care, 2026.

Global spatial distribution and risk factor profiles of Co-occurring type 2 diabetes and ischemic heart disease across 204 countries and territories

2026-11-13T18:46:09.627Z

Research article · Diabetes Res Clin Pract, 2026.

Beyond BMI: A multiparametric approach to cardiometabolic risk detection in young adults. Integrating body fat percentage and the FINDRISC score

2026-11-13T17:46:43.542Z

Meta-analysis · Diabetes Res Clin Pract, 2026.

Development and Validation of 10‐Year Prediction Models for Cardiovascular, Kidney and Metabolic Events Among Chinese Patients With Prediabetes in Hong Kong

2026-11-13T17:46:43.542Z

Diagnostic or prognostic study · Diabetes Obes Metab, 2026.

GLP ‐1 Receptor Agonists Use in Patients With Prior Psychotropic Treatment: A Nationwide Cohort Study

2026-11-13T17:46:43.542Z

Cohort study · Diabetes Obes Metab, 2026.

Health-related quality of life in early-stage type 2 diabetes: A cross-sectional study within the SMARTEST trial

2026-11-13T17:46:43.542Z

Cross-sectional study · Diabetes Res Clin Pract, 2026.

Intensive Blood-Pressure Lowering in Patients with Type 2 Diabetes

2026-11-13T17:46:43.542Z

Randomized controlled trial · N Engl J Med, 2026.

Joint triglyceride–glucose index and single-point insulin sensitivity estimator phenotypes and diabetes outcomes across three populations

2026-11-13T17:46:43.542Z

Cross-sectional study · Diabetes Res Clin Pract, 2026.

Metformin and Severe Post‐ COVID ‐19 Outcomes Among Individuals With Diabetes Mellitus

2026-11-13T17:46:43.542Z

Cohort study · Diabetes Obes Metab, 2026.

Multimorbidity patterns and disease co‐occurrence networks in older adults with diabetes: A national population‐based network analysis

2026-11-13T17:00:16.153Z

Cross-sectional study · Diabet Med, 2026.

Muscle Lipid Localization Relates to Insulin Sensitivity: Responses to Exercise and Weight Loss Interventions

2026-11-13T17:00:16.153Z

Research article · J Clin Endocrinol Metab, 2026.

Advances in the hospital management of hyperglycemia and type 2 diabetes in non-critical care settings

2026-11-13T15:47:59.646Z

Research article · BMJ Open Diabetes Res Care, 2026.

Birthweight and Glucose Tolerance Status Are Associated With Organ Sizes in Older Adults

2026-11-13T15:47:59.646Z

Cohort study · Diabetes Obes Metab, 2026.

Cognitive leisure activity and incident dementia among older adults with diabetes: a 5-year prospective cohort study

2026-11-13T15:47:59.646Z

Cohort study · Diabetes Metab, 2026.

Effectiveness of GLP ‐1 RAs and SGLT ‐2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial

2026-11-13T15:47:59.646Z

Cohort study · Diabetes Obes Metab, 2026.

Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT ‐1 Randomized Controlled Trial

2026-11-13T15:47:59.646Z

Secondary analysis · Diabetes Obes Metab, 2026.

Multidimensional assessment of the cholesterol-HDL-glucose index identifies elevated risk of incident frailty in middle-aged and older adults: longitudinal evidence from CHARLS and ELSA

2026-11-13T15:47:59.646Z

Cohort study · Diabetes Res Clin Pract, 2026.

Optimal dietary patterns for prevention of chronic disease

2026-11-13T11:02:00.546Z

Cohort study · Nat Med, 2023. Major chronic disease (composite of major CVD, T2D, cancer) — Low insulinemic vs 10th percentile: HR 0.58 (95% CI 0.57, 0.60); 90th vs 10th percentile

Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study

2026-11-13T11:02:00.546Z

Secondary analysis · Nat Med, 2022. Preferred drug: Pioglitazone 115 (25%) · Sitagliptin 158 (35%) · Canagliflozin 175 (38%)

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study

2026-11-13T11:02:00.546Z

Randomized controlled trial · Nat Med, 2022. Achieved HbA1c difference between strata for the two drugs — Pioglitazone vs Sitagliptin: difference in achieved HbA1c, body mass index (BMI) >30 vs ≤30 kg/m2 2.88 mmol/mol (95% CI 0.98, 4.79); P = 0.003; lower HbA1c on pioglitazone than sitagliptin in BMI >30; n = 356

Comparative Effectiveness of Team-Based Care With and Without a Clinical Decision Support System for Diabetes Management : A Cluster Randomized Trial

2026-11-13T11:01:36.927Z

Randomized controlled trial · Ann Intern Med, 2022. Coprimary outcomes: change in HbA1c, LDL-C, systolic BP; all 3 controlled, 18 months: Team-based care with a CDSS -0.9 (CI -0.9 to -0.8) percentage point (HbA1c change); LDL-C change -0.49 mmol/L (CI, -0.53 to -0.45); Systolic BP change -9.1 mm Hg (CI, -9.9 to -8.3); All 3 controlled 16.9% (CI, 15.7% to 18.2%) · Team-based care alone -0.6 (CI -0.7 to -0.5) percentage point (HbA1c change); LDL-C change -0.32 mmol/L (CI, -0.35 to -0.29); Systolic BP change -7.5 mm Hg (CI, -8.4 to -6.6); All 3 controlled 13.0% (CI, 11.7% to 14.3%)

Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

2026-11-13T11:01:36.927Z

Guideline or statement · Ann Intern Med, 2023.

Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial

2026-11-13T11:01:36.927Z

Randomized controlled trial · Ann Intern Med, 2022. Change in HbA1c, 6 months — LCHF vs HCLF: mean difference in change -6.1 mmol/mol (95% CI -9.2 to -3.0); greater improvement with LCHF

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials

2026-11-13T11:01:36.927Z

Meta-analysis · Ann Intern Med, 2023. New-onset diabetes — Vitamin D vs Placebo: HR 0.85 (95% CI 0.75 to 0.96); adjusted analyses; risk reduced by 15%

Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong

2026-11-13T11:00:06.281Z

Cohort study · JAMA Netw Open, 2023. SGLT2Is vs DPP4Is: HR 0.65 (95% CI 0.54-0.79); P < .001; incident OAD; matched non-OAD cohort: 5696 SGLT2I vs 22 784 DPP4I users

Continuity of Medication Use by US Adults With Diabetes, 2005-2019

2026-11-13T11:00:06.281Z

Cross-sectional study · JAMA Netw Open, 2023. Did not maintain continuity of medication use, both years of follow-up: Glucose-lowering, mean 19.5% (95% CI 18.6%-20.3%)

Evaluation of High-Deductible Health Plans and Acute Glycemic Complications Among Adults With Diabetes

2026-11-13T11:00:06.281Z

Cohort study · JAMA Netw Open, 2023. ≥1 hypoglycemia-related ED visit or hospitalization, all study years — HDHP vs Did not switch: OR 1.01 (95% CI 0.95-1.06); P = .85; switching to HDHP

Global Prevalence of Diabetic Retinopathy in Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis

2026-11-13T11:00:06.281Z

Meta-analysis · JAMA Netw Open, 2023. Global prevalence of DR in pediatric T2D: Pooled global prevalence of DR 6.99% (95% CI, 3.75%-11.00%; I2 = 95%; 615 patients)

Prevalence of Undiagnosed Diabetes Identified by a Novel Electronic Medical Record Diabetes Screening Program in an Urban Emergency Department in the US

2026-11-13T11:00:06.281Z

Cross-sectional study · JAMA Netw Open, 2023. Describes a screening program developed to screen for T2D in an urban ED setting in the US

Risk of Death Associated With Reversion From Prediabetes to Normoglycemia and the Role of Modifiable Risk Factors

2026-11-13T11:00:06.281Z

Cohort study · JAMA Netw Open, 2023. Risk of death by change in prediabetes status — Progression to diabetes vs Persistent prediabetes: HR 1.50 (95% CI 1.25-1.79); all-cause death

Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan

2026-11-13T11:00:06.281Z

Cohort study · JAMA Netw Open, 2023. AKI and AKI-D, follow-up approximately 2.50 years — SGLT2i vs DPP4i: risk (AKI) 0.66 (95% CI 0.57-0.75); P < .001; 0.66-fold risk for AKI

Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020

2026-11-13T10:59:26.873Z

Cross-sectional study · JAMA, 2023. Prevalence of cardiovascular risk factors: Hypertension prevalence, 2009-2010 9.3% (95% CI, 8.1%-10.5%)

Association of bisphosphonates with diabetes risk and glycemic control: a meta-analysis

2026-11-13T10:56:17.867Z

Meta-analysis · Osteoporos Int, 2022. Risk of diabetes — BPs vs Controls: RR 0.77 (95% CI 0.65 to 0.90); P = 0.002

Effect of exercise training on insulin-stimulated glucose disposal: a systematic review and meta-analysis of randomized controlled trials

2026-11-13T10:51:50.896Z

Meta-analysis · Int J Obes (Lond), 2023. Insulin-stimulated glucose disposal — Exercise vs Control: SMD 0.52 (95% CI 0.39, 0.65); p < 0.001; I2 = 47%

Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment

2026-11-13T10:51:50.896Z

Cohort study · Int J Obes (Lond), 2023. MACE or all-cause mortality, 8-year cumulative incidence: Non-surgical patients with MACE or all-cause mortality (8-year cumulative incidence 11.3%) 130

Circadian rhythm parameters and physical activity associated with cardiometabolic risk factors in the PREVIEW lifestyle study

2026-11-13T10:47:54.884Z

Secondary analysis · Obesity (Silver Spring), 2023. after 3 years of weight loss maintenance: Cardiometabolic risk factor values similar between conditions; circadian rhythm parameters and physical activity (PA) differed significantly p < 0.05

Effects of a grocery shopping intervention designed to improve diet adherence in diabetes: a randomized trial

2026-11-13T10:47:54.884Z

Randomized controlled trial · Obesity (Silver Spring), 2022. Nutritional quality of grocery purchases — Defaults vs Online: F 16.3; p < 0.001; Defaults vs other groups; significantly greater nutritional quality with Defaults

Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study

2026-11-13T10:47:54.884Z

Cohort study · Obesity (Silver Spring), 2023. Mean percent weight loss, 72 weeks: GLP-1 agonist mean 2.2% (95% CI 1.7%-2.6%)

Reproducibility and determinants of the metabolic responses during a mixed‐meal tolerance test

2026-11-13T10:47:54.884Z

Cohort study · Obesity (Silver Spring), 2023. Reproducibility of MMTT glucose/insulin responses (ICC): Without T2D, glucose AUC, breakfast vs lunch: moderate (ICCs) 0.44-0.61

Sleep duration and timing are prospectively linked with insulin resistance during late adolescence

2026-11-13T10:47:54.884Z

Cohort study · Obesity (Silver Spring), 2023. Development of IR, approximately 2 years — ≥1 h below recommendations: times more likely 2.74 (95% CI 1.0-7.4)

Social jet lag and (changes in) glycemic and metabolic control in people with type 2 diabetes

2026-11-13T10:47:54.884Z

Cohort study · Obesity (Silver Spring), 2023. baseline: Working: high social jet lag and HbA1c 1.87 mmol/mol (95% CI 0.75 to 2.99)

Trends in obesity prevalence and cardiometabolic risk factor control in US adults with diabetes, 1999–2020

2026-11-13T10:47:54.884Z

Cross-sectional study · Obesity (Silver Spring), 2023. Overall obesity, 1999–2002 → 2015–2020 46.9% → 58.1%